NS-2359: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) m Removed parameters. You can use this bot yourself. Report bugs here. |
Changed term “cocaine-experiences” to “cocaine-dependent” to better reflect the respective citation. Added a hyperlink to the Wikipedia article on Cocaine dependence. Tags: Mobile edit Mobile web edit |
||
| Line 33: | Line 33: | ||
| last5 = Wesnes | first4 = S. |
| last5 = Wesnes | first4 = S. |
||
| last1 = Wilens |
| last1 = Wilens |
||
}}</ref> phase II having been completed in 2007.<ref>[http://clinicaltrials.gov/ct2/show/NCT00467428 Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder - Full Text View - ClinicalTrials.gov<!-- Bot generated title -->]</ref> A trial exploring the effect of NS-2359 on [[cocaine]]- |
}}</ref> phase II having been completed in 2007.<ref>[http://clinicaltrials.gov/ct2/show/NCT00467428 Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder - Full Text View - ClinicalTrials.gov<!-- Bot generated title -->]</ref> A trial exploring the effect of NS-2359 on [[cocaine]]-[[Cocaine dependence|dependent]] individuals is currently ongoing.<ref>[http://clinicaltrials.gov/ct2/show/NCT00032916 Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers - 1 - Full Text View - ClinicalTrials.gov<!-- Bot generated title -->]</ref> |
||
Another scientific article on NS-2359 was recently (2011) published.<ref>{{Cite journal |
Another scientific article on NS-2359 was recently (2011) published.<ref>{{Cite journal |
||
Revision as of 21:22, 29 September 2019
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C15H19Cl2NO |
| Molar mass | 300.223 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[2] phase II having been completed in 2007.[3] A trial exploring the effect of NS-2359 on cocaine-dependent individuals is currently ongoing.[4]
Another scientific article on NS-2359 was recently (2011) published.[5] As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression.
See also
References
- ^ a b "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression".
- ^ Wilens, T. E.; Klint, T.; Adler, L.; West, S.; Wesnes, K.; Graff, O.; Mikkelsen, B. (2008). "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and Brain Functions. 4: 24. doi:10.1186/1744-9081-4-24. PMC 2442604. PMID 18554401.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder - Full Text View - ClinicalTrials.gov
- ^ Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers - 1 - Full Text View - ClinicalTrials.gov
- ^ Learned, S.; Graff, O.; Roychowdhury, S.; Moate, R.; Krishnan, K. R.; Archer, G.; Modell, J. G.; Alexander, R.; Zamuner, S.; Lavergne, A.; Evoniuk, G.; Ratti, E. (2011). "Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: Two randomized, placebo- and active-controlled clinical trials". Journal of Psychopharmacology. 26 (5): 653–662. doi:10.1177/0269881111424931. PMID 22048884.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |